Top Industry Leaders in the Theranostics Market
Latest Theranostics Companies Update:
Roche received FDA approval for Lumicist™ (flucicloviol F 18), a radiopharmaceutical for imaging prostate cancer recurrence. This expands their theranostics portfolio and provides a valuable tool for accurate diagnosis and treatment planning.
Novartis launched Lutathera™ (lutatetium Lu 177 vipivotide tetraxetan) in Europe for the treatment of neuroendocrine tumors. This marks a significant step in personalized medicine for patients with these rare cancers.
AstraZeneca signed a collaboration agreement with ImaginAb Inc. to develop novel radiopharmaceuticals for targeted alpha therapy. This partnership combines AstraZeneca's expertise in oncology with ImaginAb's innovative Alphamab platform.
GE Healthcare and Minerva Imaging entered into a strategic partnership to accelerate the commercial launch of targeted radionuclide therapies. This collaboration leverages GE Healthcare's imaging technologies and Minerva's expertise in radiopharmaceutical development.
Blue Earth Diagnostics and PKM Therapeutics are focusing on developing next-generation theranostic agents with improved targeting, efficacy, and theranostic capabilities.
List of Theranostics Key companies in the market
- Thermo Fisher Scientific Inc.
- Beckman Coulter, Inc.
- Hoffmann-La Roche Ltd
- Focus Diagnostics
- Illumina, Inc.
- Agilent Technologies, Inc.
- QIAGEN
- Abbott Laboratories
- Myriad Genetics, Inc.
- Foundation Medicine, Inc.
- AmeriPath, Inc.